ReviewIndian journal of ophthalmology2023
A review on drug-induced dry eye disease.
Review in Indian journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Fractional COLasers in medical science · 2025Trial
- Molecular landscape connecting complications of dry eye disease: mechanisms, therapeutic targets, biomarkers, and future innovations.International ophthalmology · 2026Review
- Epidemiological study of dry eye disease in Gansu Province based on mathematical modeling: analysis of regional population characteristics and identification of risk factors.Frontiers in public health · 2026Article
- Acupuncture combined with auricular acupressure for dry eye: a SPIRIT-guided protocol for a multicenter randomized controlled trial.Frontiers in medicine · 2026Article
- Electronic device exposure and dry eye symptoms among medical and nonmedical Palestinian university students: a multicenter cross-sectional study of associated factors.BMC ophthalmology · 2025Article
- Computational insights and study of drugs for dry eye disease through QSPR and MCDM approaches using topological indices.Scientific reports · 2025Article
- Dry eye: A hospital-based sociodemographic, risk and clinical classification profile.Health SA = SA Gesondheid · 2025Article
- Management of ocular adverse reactions to antiglaucoma medications-Survey of optometrists in Ghana.PLOS global public health · 2025Article
- An LC-MS/MS method for the determination of Lifitegrast in human plasma and tear and its application in the pharmacokinetic study.Bioanalysis · 2024Article
- Association between systemic medication use and severity of dry eye signs and symptoms in the DRy eye assessment and management (DREAM) study.The ocular surface · 2024Article
- Uncommon Blepharitis.Journal of clinical medicine · 2024Article
- Efficacy of indirect intense pulsed light irradiation on meibomian gland dysfunction: a randomized controlled study.International journal of ophthalmology · 2024Article
- Recommendations for nutritional supplements for dry eye disease: current advances.Frontiers in pharmacology · 2024Review
- Assessment of tear film parameters post-treatment with commercial eyelid cleaning wipes: a pilot study.International journal of ophthalmology · 2024Article
- Dry Eye Disease in the Middle East and Northern Africa: A Position Paper on the Current State and Unmet Needs.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Seeing through tears: Understanding and managing dry eye disease.Indian journal of ophthalmology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease encompasses a broad range of etiologies and disease subtypes which have similar clinical manifestations. Medications can cause dry eye disease or symptoms of dryness as a side effect by either interfering with the lacrimal gland or meibomian gland function, or both, and by other mechanisms that affect the ocular surface homeostasis. This is important to know and recognize as eliminating the offending medication can reverse the symptoms and, in many cases, prevent further deterioration of the ocular surface inflammation. This review focuses on drugs like systemic isotretinoin and taxanes, which cause meibomian gland dysfunction; immune checkpoint inhibitors that cause lacrimal gland dysfunction; gliptins and topical antiglaucoma medications that cause cicatrizing conjunctivitis; and epidermal growth factor receptor inhibitors, fibroblast growth factor receptor inhibitors, and belantamab mafodotin, which cause mucosal epitheliopathy. Many of these medications, particularly the newer anticancer agents, have only recently been introduced for clinical use, and knowledge and awareness of their ocular side effects are still evolving. This review aims to update ophthalmologists on the drug-induced causes of dry eye disease or symptoms of dryness, which is avoidable by discontinuation of the incriminating agent or can be mitigated by reducing the dose or frequency of usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.